Cargando…
Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-o...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222321/ https://www.ncbi.nlm.nih.gov/pubmed/34162896 http://dx.doi.org/10.1038/s41598-021-89451-6 |
_version_ | 1783711470758920192 |
---|---|
author | Vakrou, Styliani Liu, Yamin Zhu, Li Greenland, Gabriela V. Simsek, Bahadir Hebl, Virginia B. Guan, Yufan Woldemichael, Kirubel Talbot, Conover C. Aon, Miguel A. Fukunaga, Ryuya Abraham, M. Roselle |
author_facet | Vakrou, Styliani Liu, Yamin Zhu, Li Greenland, Gabriela V. Simsek, Bahadir Hebl, Virginia B. Guan, Yufan Woldemichael, Kirubel Talbot, Conover C. Aon, Miguel A. Fukunaga, Ryuya Abraham, M. Roselle |
author_sort | Vakrou, Styliani |
collection | PubMed |
description | Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-obstructive HCM (R403Q-MyHC, R92W-TnT)/littermate-control hearts at 24 weeks of age, and in myectomy tissue of patients with obstructive HCM/control hearts (GSE36961, GSE36946). Additionally, we examined myocyte redox, cardiac mitochondrial DNA copy number (mtDNA-CN), mt-respiration, mt-ROS generation/scavenging and mt-Ca(2+) handling in mice. We identified distinct allele-specific gene expression in mouse-HCM, and marked differences between mouse-HCM and human-HCM. Only two genes (CASQ1, GPT1) were similarly dysregulated in both mutant mice and human-HCM. No signaling pathway or transcription factor was predicted to be similarly dysregulated (by Ingenuity Pathway Analysis) in both mutant mice and human-HCM. Losartan was a predicted therapy only in TnT-mutant mice. KEGG pathway analysis revealed enrichment for several metabolic pathways, but only pyruvate metabolism was enriched in both mutant mice and human-HCM. Both mutant mouse myocytes demonstrated evidence of an oxidized redox environment. Mitochondrial complex I RCR was lower in both mutant mice compared to controls. MyHC-mutant mice had similar mtDNA-CN and mt-Ca(2+) handling, but TnT-mutant mice exhibited lower mtDNA-CN and impaired mt-Ca(2+) handling, compared to littermate-controls. Molecular profiling reveals differences in gene expression, transcriptional regulation, intracellular signaling and mt-number/function in 2 mouse models at established disease stage. Further studies are needed to confirm differences in gene expression between mouse and human-HCM, and to examine whether cardiac phenotype, genotype and/or species differences underlie the divergence in molecular profiles. |
format | Online Article Text |
id | pubmed-8222321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82223212021-06-24 Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy Vakrou, Styliani Liu, Yamin Zhu, Li Greenland, Gabriela V. Simsek, Bahadir Hebl, Virginia B. Guan, Yufan Woldemichael, Kirubel Talbot, Conover C. Aon, Miguel A. Fukunaga, Ryuya Abraham, M. Roselle Sci Rep Article Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-obstructive HCM (R403Q-MyHC, R92W-TnT)/littermate-control hearts at 24 weeks of age, and in myectomy tissue of patients with obstructive HCM/control hearts (GSE36961, GSE36946). Additionally, we examined myocyte redox, cardiac mitochondrial DNA copy number (mtDNA-CN), mt-respiration, mt-ROS generation/scavenging and mt-Ca(2+) handling in mice. We identified distinct allele-specific gene expression in mouse-HCM, and marked differences between mouse-HCM and human-HCM. Only two genes (CASQ1, GPT1) were similarly dysregulated in both mutant mice and human-HCM. No signaling pathway or transcription factor was predicted to be similarly dysregulated (by Ingenuity Pathway Analysis) in both mutant mice and human-HCM. Losartan was a predicted therapy only in TnT-mutant mice. KEGG pathway analysis revealed enrichment for several metabolic pathways, but only pyruvate metabolism was enriched in both mutant mice and human-HCM. Both mutant mouse myocytes demonstrated evidence of an oxidized redox environment. Mitochondrial complex I RCR was lower in both mutant mice compared to controls. MyHC-mutant mice had similar mtDNA-CN and mt-Ca(2+) handling, but TnT-mutant mice exhibited lower mtDNA-CN and impaired mt-Ca(2+) handling, compared to littermate-controls. Molecular profiling reveals differences in gene expression, transcriptional regulation, intracellular signaling and mt-number/function in 2 mouse models at established disease stage. Further studies are needed to confirm differences in gene expression between mouse and human-HCM, and to examine whether cardiac phenotype, genotype and/or species differences underlie the divergence in molecular profiles. Nature Publishing Group UK 2021-06-23 /pmc/articles/PMC8222321/ /pubmed/34162896 http://dx.doi.org/10.1038/s41598-021-89451-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vakrou, Styliani Liu, Yamin Zhu, Li Greenland, Gabriela V. Simsek, Bahadir Hebl, Virginia B. Guan, Yufan Woldemichael, Kirubel Talbot, Conover C. Aon, Miguel A. Fukunaga, Ryuya Abraham, M. Roselle Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title | Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title_full | Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title_fullStr | Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title_full_unstemmed | Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title_short | Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
title_sort | differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222321/ https://www.ncbi.nlm.nih.gov/pubmed/34162896 http://dx.doi.org/10.1038/s41598-021-89451-6 |
work_keys_str_mv | AT vakroustyliani differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT liuyamin differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT zhuli differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT greenlandgabrielav differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT simsekbahadir differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT heblvirginiab differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT guanyufan differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT woldemichaelkirubel differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT talbotconoverc differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT aonmiguela differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT fukunagaryuya differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy AT abrahammroselle differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy |